Experimental Hematology & Oncology

Papers
(The TQCC of Experimental Hematology & Oncology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Complex roles of cAMP–PKA–CREB signaling in cancer204
CD44 as a tumor biomarker and therapeutic target173
Leukemia incidence trends at the global, regional, and national level between 1990 and 2017121
Risk factors and outcome of COVID-19 in patients with hematological malignancies109
SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients65
Engineering better chimeric antigen receptor T cells63
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC63
Research progress on dendritic cell vaccines in cancer immunotherapy61
A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–201758
YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition55
Macrophage, the potential key mediator in CAR-T related CRS53
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies52
Role of m6A writers, erasers and readers in cancer48
MiRNA-mediated EMT and CSCs in cancer chemoresistance46
Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma45
Recent advances and challenges of bispecific antibodies in solid tumors42
Heterogeneity of the tumor immune microenvironment and its clinical relevance41
Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes41
VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder41
AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL40
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment40
COVID-19 vaccination associated severe immune thrombocytopenia36
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma35
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development35
Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients35
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia34
Breast cancer heterogeneity and its implication in personalized precision therapy33
PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma31
Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy31
Exosomes from BM-MSCs promote acute myeloid leukemia cell proliferation, invasion and chemoresistance via upregulation of S100A429
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma28
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors28
Roles of the intestinal microbiota and microbial metabolites in acute GVHD28
m6A binding protein YTHDF2 in cancer27
Recent advances in Lynch syndrome27
Current insight into the regulation of PD-L1 in cancer26
The role of neutrophil extracellular traps in cancer progression, metastasis and therapy26
TCR engineered T cells for solid tumor immunotherapy25
The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 201725
Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment24
Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas24
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors24
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China22
Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 si22
TRIM family contribute to tumorigenesis, cancer development, and drug resistance22
Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma21
Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia21
Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas21
Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome20
Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma20
Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study20
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy20
Increasing cure rates of solid tumors by immune checkpoint inhibitors19
A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation18
Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review18
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance18
Spindle and kinetochore-associated complex subunit 3 could serve as a prognostic biomarker for prostate cancer18
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin18
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes17
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis17
Tanshinone IIA attenuates the stemness of breast cancer cells via targeting the miR-125b/STARD13 axis17
Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside17
Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infectio16
Function and clinical significance of N6-methyladenosine in digestive system tumours16
SEPHS1 promotes SMAD2/3/4 expression and hepatocellular carcinoma cells invasion15
The metabolic adaptation mechanism of metastatic organotropism15
Recent updates for antibody therapy for acute lymphoblastic leukemia15
Gut fungi enhances immunosuppressive function of myeloid-derived suppressor cells by activating PKM2-dependent glycolysis to promote colorectal tumorigenesis15
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases15
p53 amyloid aggregation in cancer: function, mechanism, and therapy15
The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers15
Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy15
Applications of gut microbiota in patients with hematopoietic stem-cell transplantation14
Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma14
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleuce14
METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression14
Frontiers in the COVID-19 vaccines development14
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation14
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential13
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma13
Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models13
Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment13
ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner13
Targeting metabolic reprogramming in chronic lymphocytic leukemia13
Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort13
RHO GTPase family in hepatocellular carcinoma13
0.027128934860229